Members of the seven-transmembrane receptor (7TMR), or G protein-coupled receptor
(GPCR), superfamily represent some of the most successful targets of modern drug therapy …

Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that
exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its …

It is useful to consider seven transmembrane receptors (7TMRs) as disordered proteins able
to allosterically respond to a number of binding partners. Considering 7TMRs as allosteric …

Targeting neuroendocrine tumors expressing somatostatin receptor subtypes (sst) with
radiolabeled somatostatin agonists is an established diagnostic and therapeutic approach in …

Purpose Gallium-68 is a metallic positron emitter with a half-life of 68 min that is ideal for the
in vivo use of small molecules, such as [68 Ga-DOTA, Tyr 3] octreotide, in the diagnostic …

Identified in 1973, somatostatin (SST) is a cyclic hormone peptide with a short biological half-
life. Somatostatin receptors (SSTRs) are widely expressed in the whole body, with five …

Neuroendocrine tumors have shown rising incidence mainly due to higher clinical
awareness and better diagnostic tools over the last 30 years. Functional imaging of …

Somatostatin-based radiolabeled peptides have been successfully introduced into the clinic
for targeted imaging and radionuclide therapy of somatostatin receptor (sst)–positive tumors …

Two bombesin analogs, Demobesin 4 and Demobesin 1, were characterized in vitro as
gastrin-releasing peptide (GRP) receptor agonist and antagonist, respectively, and were …

Receptors for regulatory peptides are overexpressed in a variety of human cancers. They
represent the molecular basis for in vivo imaging with radiolabeled peptide probes …